Samantha Butalid, NP
Nurse Practitioner · Vallejo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 5 years
- Graduated 2021
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Looking this up.
Hospitals listed: Zuckerberg San Francisco General Hosp & Trauma Ctr. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Samantha Butalid’s office at (707) 651-1000 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Zuckerberg San Francisco General Hosp & Trauma CtrSan Francisco, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of San Francisco Health Network, which runs 2 hospitalsPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.449, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.37, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.538, Oct 2024 – Sep 2025
See every measure and the patient survey for Zuckerberg San Francisco General Hosp & Trauma Ctr
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.37 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.538 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 667 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.76 to 1.49) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.34 (147.34 to 243.34) · 76 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.5 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 214 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 261 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,351 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.5) · 4,709 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.19 to 0.59) · 4,644 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.34 (2.11 to 6.56) · 795 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.28) · 234 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.85 (1.33 to 4.38) · 861 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.95 (0.25 to 17.64) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6 (2.01 to 9.98) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 167 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.79 (0.08 to 1.49) · 4,129 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.709 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.769 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 41 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 75.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.3 (8.3 to 15.1) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 132 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.4 to 17.9) · 966 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.7) · 88 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,644 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Drugs they prescribed that Part D paid
$95,863
Pharmacies billed $95,863 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 10% of their Part D prescriptions (20 of 211) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
193 generic and fewer than 11 brand-name prescriptions · $95,863 in drug cost · 27 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydrocodone-Acetaminophen | 13 | $652 | $50 |
| Anastrozole | 19 | $543 | $29 |
| Potassium Chloride | 14 | $409 | $29 |
| Diphenoxylate-Atropine | 29 | $350 | $12 |
| Lidocaine Hcl Viscous | 11 | $195 | $18 |
See all 6 drugs
| Hydrocodone-Acetaminophen | 13 | $652 | $50 |
| Anastrozole | 19 | $543 | $29 |
| Potassium Chloride | 14 | $409 | $29 |
| Diphenoxylate-Atropine | 29 | $350 | $12 |
| Lidocaine Hcl Viscous | 11 | $195 | $18 |
| Prednisone | 17 | $110 | $6 |
Year by year
| 2024 | 211 | 114 | 10% (20) | None | $95,863 |
| 2023 | 169 | 106 | 11% (19) | 15% | $178,819 |
| 2022 | 26 | 25 | 0% (0) | None | $27,269 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Anastrozole | 17 | $464 | $27 |
| Hydrocodone-Acetaminophen | 11 | $126 | $11 |
2022: 1 drug
| Anastrozole | 11 | $290 | $26 |
Money from drug and device companies
$420 in 2025
| 2025 | 5 | 5 | None | $420 |
| 2024 | 1 | 1 | None | $146 |
| 2023 | 6 | 7 | None | $261 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Abecma | $115 | 1 payment
|
| PharmaEssentia USA | Besremi | $111 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $109 | 1 payment
|
| Coherus Oncology | Loqtorzi | $47 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $38 | 1 payment
|
See all 5 published payments
| PharmaEssentia USA | Meals · 2025-11-19 | Besremi | $111 |
| Regeneron Healthcare Solutions | Meals · 2025-10-20 | Libtayo | $38 |
| Coherus Oncology | Meals · 2025-09-29 | Loqtorzi | $47 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-24 | Fruzaqla | $109 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-26 | Abecma | $115 |
See earlier years (2024, 2023)
2024: $146
| Gilead Sciences | None | $146 | 1 payment
|
2023: $261
| AstraZeneca Pharmaceuticals LP | None | $105 | 1 payment
|
| Genentech USA | Tecentriq | $54 | 2 payments
|
| Astellas Pharma US | Padcev | $28 | 1 payment
|
| Amgen | Nplate | $27 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $25 | 1 payment
|
| Incyte | Monjuvi | $22 | 1 payment
|
Professional record
- NPI
- 1174100010
- Licence
- CA 2970, CA 95016996
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 364SG0600X (364SG0600X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2021-03-26
- NPI last updated
- 2023-03-01
- NPI record certified
- 2022-04-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1 Quality Dr, Vacaville, CA, 95688